 SAN DIEGO, May 6, 2021 PRNewswire -- Cardiff Oncology, Inc. Nasdaq: CRDF, a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, today announced recent company highlights and financial results for the first quarter ended March 31, 2021. The Company is issuing this press release in lieu of conducting a conference call. 